Skip to main content
OpenTrials
Completed

NCT Number: NCT03427203

Assessment of New Ostomy Devices in Subjects Having an Ileostomy

The study investigates the performance of three new adhesives with regard to leakage and the skin condition.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Coloplast A/S, Humlebæk, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have given written informed consent and in DK: signed a letter of authority
  • Be at least 18 years of age and have full legal capacity
  • Have had their ileostomy for at least 3 months
  • Must be able to use custom cut product
  • Can use a product with max cut size 45 mm
  • Self-reported problems with leakage (3 x within 14 days)
  • Get a negative result of a pregnancy test for women of childbearing age (only DK)

Exclusion criteria

  • Are currently receiving or have within the past 2 months received radio-and/or chemotherapy (low doses chemotherapy are allowed for other indications than cancer, e.g. below 15 mg methotrexate for rheumatoid arthritis)
  • Are currently receiving or have within the past month received topical steroid treatment in the peristomal skin area, e.g. lotion or spray. Systemic steroid treatment (e.g. injection, or tablet) are allowed.
  • Are pregnant or breastfeeding
  • Are participating in other interventional clinical investigations or have previously participated in this investigation 4.1. Exception: Participation in other Coloplast in-house clinical investigations are accepted under the circumstances that the subject has paused the activities in the investigation and are otherwise complying with the inclusion and exclusion criteria of this (CP264) protocol.
  • Are currently suffering from peristomal skin problems i.e. bleeding and/or broken skin (assessed by the investigator)
  • Have known hypersensitivity towards any of the products used in the investigation

Treatment and study plan

SenSura Mio

Device

SenSura Mio is a marked ostomy device which is used as the comparator in this study

Coloplast Ostomy device 1

Device

Coloplast Ostomy device 1 a newly developed ostomy device

Coloplast ostomy device

Device

Coloplast Ostomy device 2 a newly developed ostomy device

Coloplast Ostomy device 3

Device

Coloplast Ostomy device 3 a newly developed ostomy device

Primary outcomes

  1. Trans epidermal water loss

    Time frame: 14 days

    Trans epidermal water loss is an objective skin measurement that is measures the evaporation of water on the skin surface using a probe (DermaLab).The trans epidermal water loss is a measure for the skins barrier function. There is always aloss of water from the skin due to evaporation. When the skin barrier is damaged this evaporation of water increases. Thus, transepidermal water loss can be used to assess skin damage

Sponsors and collaborators

Lead sponsor

Coloplast A/S

Industry

Registry information

Official study title

Assessment of New Enhanced Ostomy Devices in Real-life Set-tings in Subjects Having an Ileostomy

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Feb 9, 2018
Registry last updated
Jun 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.